Desferal

(Deferoxamine Mesylate)

Phase 3Small molecule

Jazz Pharmaceuticals

Desferal is one of 41 small molecule programs targeting Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

StrokeRecruiting

StrokePhase 3

Recruiting

Competition

Competitive Landscape

150 competitors in Stroke

#DrugCompanyPhaseTrials

Desferal

Jazz Pharmaceuticals

Phase 3

1 2

Zometa

Pfizer

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Proamatine

Repatha

Zantac 150

1 7

Alka-Seltzer

AAbbott

Preclinical

1 8

Haldol

DDePuy Orthopaedics

Preclinical

1 9

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Recruiting

Intracerebral Hemorrhage

NCT06763055

Q3 2034

Phase 3Recruiting

Stroke

NCT06352632

Clinical

Trials by Indication[1]

Intracerebral Hemorrhage2 trials

Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

Completed·—·Phase 2·NCT02175225·294 enrolled

The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL

Recruiting·TThe George Institute·Phase 3·NCT06763055·2,000 enrolled

Hemorrhage1 trial

Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage

Completed·—·Phase 1·NCT00598572·20 enrolled

Stroke1 trial

A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL)

Recruiting·TThe George Institute·Phase 3·NCT06352632·20,000 enrolled

Regulatory

FDA Approval Timeline[4]

May 25, 2000

DESFERAL

NDA NDA016267

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Deferoxamine Mesylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Deferoxamine Mesylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Deferoxamine Mesylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA016267). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Jazz Pharmaceuticals

Desferal

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2034

Trials by Indication[1]

Intracerebral Hemorrhage2 trials

Hemorrhage1 trial

Stroke1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News